Low concentrations of STI571 in the cerebrospinal fluid:: a case report

被引：82

作者：

Petzer, AL

Gunsilius, E

Hayes, M

Stockhammer, G

Duba, HC

Schneller, F

Grünewald, K

Poewe, W

Gastl, G

机构：

[1] Univ Klin Innsbruck, Abt Hamatol & Onkol, A-6020 Innsbruck, Austria

[2] Novartis Pharmaceut, E Hanover, NJ USA

[3] Univ Innsbruck, Neurol Klin, A-6020 Innsbruck, Austria

[4] Univ Innsbruck, Inst Med Biol & Human Genet, Innsbruck, Austria

[5] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 3, D-8000 Munich, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 117卷 / 03期

关键词：

STI571; tyrosine kinase inhibitor; chronic myeloid leukaemia; ALL;

D O I：

10.1046/j.1365-2141.2002.03523.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report a 53-year-old man with lymphoid blast crisis of Ph(+) chronic myeloid leukaemia who was treated with STI571, a selective inhibitor of the enzymatic activity of BCR-ABL. He responded excellently to STI571 (600 mg/d), obtaining a complete cytogenetic remission after 3 months of therapy. Although remission in the bone marrow was sustained, the patient developed an isolated central nervous system relapse. Subsequent analyses of STI571 concentrations in the cerebrospinal fluid (CSF) revealed 2-log lower CSF levels of STI571 than corresponding plasma levels. These are the first data demonstrating a low penetration of orally administered STI571 into the CSF in humans.

引用

页码：623 / 625

页数：3

共 8 条

[1]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[2] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].